Indaptus Therapeutics (NASDAQ:INDP) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Indaptus Therapeutics (NASDAQ:INDP) posted its quarterly earnings data on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.03, Zacks reports.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ INDP opened at $0.81 on Friday. The business’s 50 day moving average price is $0.86 and its 200-day moving average price is $1.08. Indaptus Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $3.10. The company has a market cap of $11.37 million, a price-to-earnings ratio of -0.47 and a beta of 1.60.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.